MUFG Americas’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

MUFG Americas’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-445	Closed	-$10K	–	1054
2017 Q4	$10K	Buy	445 +303	+213%	+$9.74K	﹤0.01%	860
2017 Q3	$6K	Sell	142 -306	-68%	-$9.61K	﹤0.01%	930
2017 Q2	$13K	Hold	448	–	–	﹤0.01%	805
2017 Q1	$16K	Buy	448 +72	+19%	+$3.17K	﹤0.01%	768
2016 Q4	$19K	Sell	376 -137	-27%	-$7.2K	﹤0.01%	730
2016 Q3	$27K	Sell	513 -112	-18%	-$5.35K	﹤0.01%	669
2016 Q2	$26K	Buy	625 +176	+39%	+$7.66K	﹤0.01%	651
2016 Q1	$18K	Buy	+449	New	+$15.4K	﹤0.01%	731
2015 Q4	–	Sell	-113	Closed	-$2K	–	1254
2015 Q3	$2K	Hold	113	–	–	﹤0.01%	1126
2015 Q2	$3K	Buy	+113	New	+$2.52K	﹤0.01%	1056

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

MUFG Americas's FPRX Position: Q1 2018 in Review

MUFG Americas sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 445 shares — an estimated $10K sold.

MUFG Americas first reported a position in FPRX in Q2 2015 and held it in 10 quarters. The position peaked at $27K in Q3 2016. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

MUFG Americas reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
MUFG Americas sold 445 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $10K.
MUFG Americas first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 10 quarters.
MUFG Americas's Five Prime Therapeutics, Inc. position peaked at $27K in Q3 2016.
128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on MUFG Americas's 13F filing for Q1 2018, filed 7 May 2018.